Transcript PowerPoint-presentasjon

Dag Berild 2014
Dag Berild 2014
No new antibiotics the last decades
Dag Berild 2014
Thank you for your attention
Dag Berild 2014
We are afraid of resistance because
•
•
•
•
•
Mortality and morbidity increases
Hospital & society costs increases
Modern medicine becomes impossible
We can die of common infection
No new antibiotics coming up!
Dag Berild 2014
We can reduce resistance
•
•
•
•
•
•
Reduce total and broad spectrum ABs
Vaccination
Shorten therapy
Use small spectrum AB
Stop using AB in upper respiratory tract inf.
Adjust therapy according to bacteriological
findings
• Education
Dag Berild 2014
The cost of resistance
Country
Bactreiae
Additional cost for
ABR per patient
Adittional LOS due
to ABR per patient
US
MRSA/MSSA
$ 21000-25000
US
ABR/non-ABR
infections
$ 29000
6.4-12.7 days
US
HAI by Gramnegative bacteria
29% higer costs
24% longer stay
US
MRSA/MSSA (SSI
infections)
$ 24000
6 days
Israel
ESBL-prod-bacteria
57% higer costs
56% longer stay
Spain
Resistant
K.pneumoniae
29 additional days
Dag Berild 2014
Financial and other costs
Region
Costs
Deaths
Lost
productivity
Comments
Europe
EUR 1.5 bn/y
25000 in EU
600 mill days
Russia 83%
wrong use
North America
$21-34 bn/y
40000
Thailand
30000
Tanzania
Mortality x 2 of
malaria (cildr)
Peru
>51% HAI
caused by ARB
Pakistan
71% newborn
by ABR
Dag Berild 2014
Public & politicans perception of
apocalypse by infections
•
•
•
•
•
AIDS
Ebola
Samonella
Mad-cow disease
Horse meat!!
Dag Berild 2014
In 1973 more than half of antibiotic use was superflous
or wrong
Dag Berild 2014
Nytt, norsk antibiotikum mot MRSA og VRE ?
Methicillin Resistant Staphylococcus Aureus
Vancomycin Resistant Enterococcus
•
Rutinemessig vannprøve analysert på
Veterinærhøyskolen påviste en bakterie som
produserte en oppklaringssone
•
•
Isolert: Syklisk lipopeptid fra Pseudomonas fluorescens
Antimikrobielt spektrum:
Gram positive, deriblant MRSA og
VRE
MIC verdi 4-8ug/ml
•
Varme/syre/protease-stabilt
---> oral administrasjonsform…
Arbeid gjenstår før anvendbart legemiddel:
•Produksjon
•Dokumentasjon (in vitro + in vivo)
•Markedsføringstillatelse
Slike ting kan gjøres i Norge !!
Inven2 har: • Teknologiforståelse
• Patentadvokater
• Businessfolk og industrikontakt
• Sugerør til finansiering
Men vi trenger en
prosjektleder!!!
Ring/mail Magne - kontaktinfo på11
www.inven2.com
From Science to
Business
Magne Rekvig
Lege / Forsker / «Technology Strategy Manager»
From Science to Business
www.inven2.com
[email protected]
mob: 41 01 13 46
7/16/2015
We can loose antibiotics because
• It is a complx society problem with ecological
consequences
• Enormous ecomomic/political implications
• The medical society has noe solutions, it is a
problem of morality
• A tragedy of the common goods
Dag Berild 2014
Apocalyptic scenario
Developed countries
Low income countries
• ESBL continous to increase
• Transplantations, chemo,
prostesis surgery hampered
• MRSA stabilised
• Expensive antibiotics
avaliable?
• Health refugees
• Millions die from TB
• Septicaemia and menigitis
untreatable
• Gonhorrea untreatable
• No cure for malaria
• Malnourishment and HIV
increases bacterial mortality
Dag Berild 2014
Resistance increases death rate
Bacteria
Death rate resistant strain
Death rate sensitive strain
E. coli
32%
17%
A.baumannii
16,4%
5,4%
A.baumannii
53,8%
31,0% Ω
K.pneumoniae
42,9%
18,9%
K.pneumoniae
43,8%
12,5%
K.pneumoniae
38%
12%
S.aureus
36,4%
27,0%
S.aureus
23,6%
11,5%
Dag Berild 2014